Edgewise Therapeutics (EWTX) financial statements
Net income was -$168M.
Free cash flow was -$144M.
The diluted share count rose 13828% over the period (dilution).
Income statement
Fiscal years, from Edgewise Therapeutics's 10-K filings with the SEC.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Research and development | $15M | $32M | $54M | $91M | $127M | $151M |
| Selling, general and admin | $2M | $11M | $18M | $23M | $32M | $40M |
| Operating income | -$17M | -$43M | -$72M | -$114M | -$159M | -$191M |
| Pre-tax income | — | — | — | -$100M | -$134M | -$168M |
| Income tax | — | $0 | $0 | $4,000 | $3,000 | $4,000 |
| Net income | -$17M | -$43M | -$68M | -$100M | -$134M | -$168M |
| EPS (diluted) | -$23.17 | -$1.14 | -$1.26 | -$1.57 | -$1.45 | -$1.63 |
| Diluted shares | 1M | 38M | 54M | 64M | 92M | 103M |
Balance sheet
Fiscal years, from Edgewise Therapeutics's 10-K filings with the SEC.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Cash and short-term investments | $105M | $16M | $22M | $86M | $42M | $61M |
| Total current assets | $130M | $284M | $357M | $327M | $475M | $543M |
| Property, plant and equipment | $516,000 | $912,000 | $9M | $10M | $10M | $8M |
| Total assets | $131M | $285M | $367M | $340M | $487M | $553M |
| Total current liabilities | $4M | $11M | $17M | $17M | $24M | $27M |
| Total liabilities | $4M | $11M | $20M | $21M | $28M | $30M |
| Shareholders' equity | -$33M | $274M | $347M | $319M | $459M | $522M |
| Net debt | -$105M | -$16M | -$22M | -$86M | -$42M | -$61M |
Cash flow
Fiscal years, from Edgewise Therapeutics's 10-K filings with the SEC.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$15M | -$34M | -$53M | -$92M | -$109M | -$144M |
| Capital spending | $203,000 | $668,000 | $6M | $6M | $1M | $256,000 |
| Free cash flow | -$15M | -$34M | -$58M | -$98M | -$110M | -$144M |
| Stock-based compensation | $354,000 | $4M | $11M | $18M | $25M | $35M |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for EWTX.
Open EWTX in InvestinglyQuestions
How much free cash flow does Edgewise Therapeutics generate?
-$144M in fiscal 2025 (operating cash flow minus capital spending).
From Edgewise Therapeutics's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.